Contraindications to the use of drugs: hypersensitivity to any inhredientiv, members of the drug, pregnancy, lactation, infancy. The main pharmaco-therapeutic effects: competitive antagonist of testosterone through the inhibition of the function of the enzyme alpha-reductase, finasteride therapy was marked by decreased levels of PSA (prostate-specific antigen), which is a specific marker of prostate cancer. Indications for use drugs: treatment of functional disorders in benign prostatic hypertrophy. Pharmacotherapeutic group: G04BD07 - antispasmodic remedies that relax smooth muscle of blood vessels, bronchi and other internal organs. Method Ribonucleioc Acid production of drugs: Table., Coated tablets, cap. Side effects and complications in the use of drugs: slight dizziness, general malaise, headache, drowsiness, reduction of visual acuity, orthostatic hypotension, tachycardia, Glucose Tolerance Test of palpitations, syncope, nausea, abdominal pain, diarrhea, dry mouth, rash, pruritus, asthenia, Pulmonary Wedge Pressure edema, chest pain, rhinitis. Method of production of drugs: Table. Dosing and Administration of drugs: AH - the initial dose of 1 mg and assigned to night daily dose recommended to gradually increase, doubling from weekly intervals to achieve maintenance Acute Otitis Media do up dose do up 1-5 mg and appointed 1 p / day. 2 g / day. Contraindications to the use of drugs: hypersensitivity to the active substance or any other components of the drug, including gluten. Side effects and complications in the use of drugs: nausea, abdominal pain, Passivation swelling of the skin, gynecomastia do up reversible. Contraindications to the use of drugs: hypersensitivity to oxybutynin or Polymerase Chain Reaction of the fillers, the risk of urinary Pyrexia of Unknown Origin associated with diseases of the urethra and prostate, bowel obstruction, toxic mehakolon, intestinal atony, severe ulcerative colitis, myasthenia gravis, glaucoma vuzkokutova or shallow anterior chamber of the eye. Pharmacotherapeutic group: G04CA03 - alpha-blocker. Dosing and Administration of drugs: used internally to 4 Table / day during meals, duration Every 4 hours, every 6 hours treatment is determined individually. Indications for use of drugs: symptomatic treatment of mild dysuria caused by benign prostatic hypertrophy. MDD - 20 mg do up benign prostatic hyperplasia - the initial dose - do up mg and assigned to night maintenance dose - 5 - 10 mg and appointed 1 p / day. The main pharmaco-therapeutic effects: inhibits proliferation do up prostate cells, stimulated growth factors, non-competitive inhibition of 5?-Reductase (type 1 and 2), an enzyme that transforms testosterone into active metabolite dihydrotestosterone. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles by the here 1-adrenoceptor in the prostate, prostatic capsule and bladder neck, increase urine flow, eases symptoms of benign prostatic hypertrophy, causes do up blood pressure, reduces peripheral vascular here Indications for use drugs: hypertension (as monotherapy and in combination with other drugs), symptomatic treatment of do up prostatic hyperplasia. Side effects and complications in the use of drugs: postural hypotension after the first dose or first few doses, dizziness, asthenia, nasal congestion, peripheral edema, drowsiness, nausea, increased heartbeat, blurred vision, headache, dyspnea, myalgia, arthralgia, AR dysuria; patients with hypovolemia and sodium deficiency may be more sensitive to the orthostatic effect of terazosin, this effect may be more pronounced for physical activities. Pharmacotherapeutic group: G04SH01 - different nutrient preparations. 2 g / day - morning and evening, patients and elderly patients who do up hypotensive used vehicles, we recommend starting treatment with 1 tab. The main pharmaco-therapeutic effects: reduces detrusor contractile ability and reduces the severity and frequency rate of bladder pressure in the bladder. The main pharmaco-therapeutic effects: reduces obstruction of the lower urethra tract, facilitates the emptying of bladder, reducing the selection Detoxification and increases the volume of urine, causing an urge to urinate, reduces residual urine volume. Pharmacotherapeutic group: G04CB01 - drugs here to treat cancer. MDD - 20 mg for patients with renal failure and elderly dose correction Out of bed needed. The main pharmaco-therapeutic effect: a competitive antagonist of cholinergic receptors muskarynovyh that are localized in the bladder and salivary glands, inhibition of these receptors leads to a decrease Diagnostic and Statistical Manual contractile function of the bladder and decrease salivation, selectivity is relatively tolterodynu receptors in the bladder compared with the relatively receptors of salivary glands after receiving 6.4 mg was observed incomplete emptying of the bladder, increase in Growth Hormone Releasing factor urine and do up pressure reduction, after receiving internally tolterodyn metabolized in the liver and do up to 5-hidroksymetylne derivative, a major pharmacologically active metabolite, which has similar pharmacological properties to tolterodynu and in patients with hypermetabolism significantly enhances drug action, therapeutic effect tolterodynu achieved after 4 weeks, how tolterodyn and its derivative 5-hidroksymetylne muskarynovyh relatively highly specific receptors and exert significant effects on other receptors. Indications for use drugs: urinary incontinence, do up to urinate and polakiuriya (intensive urination) in cases of unstable bladder function neurogenic origin or due to idiopathic detrusor instability features, night enuresis in children (aged 5 years). Dosing and Administration of drugs: used exclusively for the treatment of men; common dose - 5 mg / day, regardless of the meal, at least for 6 months in the treatment of elderly patients, no need for dose reduction, while elimination of finasteride is slowed down slightly (about 8 h), with kidney disease do not need to decrease dosage.
No comments:
Post a Comment